320 related articles for article (PubMed ID: 26998221)
1. Mechanisms of doxorubicin resistance in hepatocellular carcinoma.
Cox J; Weinman S
Hepat Oncol; 2016 Jan; 3(1):57-59. PubMed ID: 26998221
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase SIRT6 regulates chemosensitivity in liver cancer cells via modulation of FOXO3 activity.
Hu JQ; Deng F; Hu XP; Zhang W; Zeng XC; Tian XF
Oncol Rep; 2018 Dec; 40(6):3635-3644. PubMed ID: 30542728
[TBL] [Abstract][Full Text] [Related]
3. Ultrasound-guided therapeutic modulation of hepatocellular carcinoma using complementary microRNAs.
Mullick Chowdhury S; Wang TY; Bachawal S; Devulapally R; Choe JW; Abou Elkacem L; Yakub BK; Wang DS; Tian L; Paulmurugan R; Willmann JK
J Control Release; 2016 Sep; 238():272-280. PubMed ID: 27503707
[TBL] [Abstract][Full Text] [Related]
4. F127 poloxamer effect on cytotoxicity induction of tumour cell cultures treated with doxorubicin.
Gentile EA; Castronuovo CC; Cuestas ML; Gómez N; Davio C; Oubiña JR; Mathet VL
J Pharm Pharmacol; 2019 Nov; 71(11):1655-1662. PubMed ID: 31456253
[TBL] [Abstract][Full Text] [Related]
5. Codelivery of Doxorubicin and Verapamil for Treating Multidrug Resistant Cancer Cells.
Williams JB; Buchanan CM; Pitt WG
Pharm Nanotechnol; 2018; 6(2):116-123. PubMed ID: 30207210
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular carcinoma cells surviving doxorubicin treatment exhibit increased migratory potential and resistance to doxorubicin re-treatment
Buschauer S; Koch A; Wiggermann P; Müller M; Hellerbrand C
Oncol Lett; 2018 Apr; 15(4):4635-4640. PubMed ID: 29541235
[TBL] [Abstract][Full Text] [Related]
7. siRNA Targeting of MDR1 Reverses Multidrug Resistance in a Nude Mouse Model of Doxorubicin-resistant Human Hepatocellular Carcinoma.
Yang H; Ding R; Tong Z; Huang J; Shen L; Sun YU; Liao J; Yang Z; Hoffman RM; Wang C; Meng X
Anticancer Res; 2016 Jun; 36(6):2675-82. PubMed ID: 27272776
[TBL] [Abstract][Full Text] [Related]
8. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
[TBL] [Abstract][Full Text] [Related]
9. SIRT7 regulates hepatocellular carcinoma response to therapy by altering the p53-dependent cell death pathway.
Zhao J; Wozniak A; Adams A; Cox J; Vittal A; Voss J; Bridges B; Weinman SA; Li Z
J Exp Clin Cancer Res; 2019 Jun; 38(1):252. PubMed ID: 31196136
[TBL] [Abstract][Full Text] [Related]
10. Reversal effect of quercetin on multidrug resistance via FZD7/β-catenin pathway in hepatocellular carcinoma cells.
Chen Z; Huang C; Ma T; Jiang L; Tang L; Shi T; Zhang S; Zhang L; Zhu P; Li J; Shen A
Phytomedicine; 2018 Apr; 43():37-45. PubMed ID: 29747752
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
12. MDR1 gene expression: its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines.
Park JG; Lee SK; Hong IG; Kim HS; Lim KH; Choe KJ; Kim WH; Kim YI; Tsuruo T; Gottesman MM
J Natl Cancer Inst; 1994 May; 86(9):700-5. PubMed ID: 7908989
[TBL] [Abstract][Full Text] [Related]
13. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
[TBL] [Abstract][Full Text] [Related]
14. Multifactorial involvement of multidrug resistance-associated [correction of resistance] protein, DNA topoisomerase II and glutathione/glutathione-S-transferase in nonP-glycoprotein-mediated multidrug resistance in human bladder cancer cells.
Kim WJ; Kakehi Y; Yoshida O
Int J Urol; 1997 Nov; 4(6):583-90. PubMed ID: 9477189
[TBL] [Abstract][Full Text] [Related]
15. Effect of Y6, an epigallocatechin gallate derivative, on reversing doxorubicin drug resistance in human hepatocellular carcinoma cells.
Wen Y; Zhao RQ; Zhang YK; Gupta P; Fu LX; Tang AZ; Liu BM; Chen ZS; Yang DH; Liang G
Oncotarget; 2017 May; 8(18):29760-29770. PubMed ID: 28423656
[TBL] [Abstract][Full Text] [Related]
16. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells.
Stein U; Walther W; Shoemaker RH
J Natl Cancer Inst; 1996 Oct; 88(19):1383-92. PubMed ID: 8827016
[TBL] [Abstract][Full Text] [Related]
17. Indomethacin and SC236 enhance the cytotoxicity of doxorubicin in human hepatocellular carcinoma cells via inhibiting P-glycoprotein and MRP1 expression.
Ye CG; Wu WK; Yeung JH; Li HT; Li ZJ; Wong CC; Ren SX; Zhang L; Fung KP; Cho CH
Cancer Lett; 2011 May; 304(2):90-6. PubMed ID: 21377266
[TBL] [Abstract][Full Text] [Related]
18. Melatonin reverses tunicamycin-induced endoplasmic reticulum stress in human hepatocellular carcinoma cells and improves cytotoxic response to doxorubicin by increasing CHOP and decreasing survivin.
Fan L; Sun G; Ma T; Zhong F; Lei Y; Li X; Wei W
J Pineal Res; 2013 Sep; 55(2):184-94. PubMed ID: 23711089
[TBL] [Abstract][Full Text] [Related]
19. Combined use of tamoxifen, cyclosporin A, and verapamil for modulating multidrug resistance in human hepatocellular carcinoma cell lines.
Kim JH; Chung JB; Park IS; Kim BS; Yoo NC; Choi JH; Roh JK; Kim HS; Kwon OH; Lee KS
Yonsei Med J; 1993 Mar; 34(1):35-44. PubMed ID: 8397460
[TBL] [Abstract][Full Text] [Related]
20. Lgr5-mediated p53 Repression through PDCD5 leads to doxorubicin resistance in Hepatocellular Carcinoma.
Ma Z; Guo D; Wang Q; Liu P; Xiao Y; Wu P; Wang Y; Chen B; Liu Z; Liu Q
Theranostics; 2019; 9(10):2967-2983. PubMed ID: 31244936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
